

Practitioner's Docket No. 700953-54440

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Ronald Levy et al.

Application No.: 10/660,369

Group No.: 1614

Filed: September 11, 2003

Examiner: To be assigned

For: TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1, AND LFA-3 AND INDUCE IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN VIVO


**CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being sent via facsimile on the date shown below to the Mail Stop Missing Parts, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

January 22, 2004

Date

Linda M. Ginsberg  
(type or print name of person mailing paper)

  
Signature of person mailing paper

**Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450**

**REQUEST FOR CORRECTED FILING RECEIPT**

1. Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.
2. There is an error with respect to the following data, which is:

incorrectly entered

*and/or*

omitted.

In re application of: Ronald Levy et al.  
Application No.: 10/660,369 Group No.: 1614  
Filed: September 11, 2003 Examiner: To be assigned  
For: TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL  
COSTIMULATORY MOLECULES B7.1, ICAM-1, AND LFA-3 AND INDUCE  
IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN VIVO

<i>Error in</i>	<i>Correct data</i>
1. [ ] Applicant's name	1.
2. [ ] Applicant's address	2.
3. [X] Title	3. TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1, AND LFA-3 AND INDUCE IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN VIVO
4. [ ] Filing Date	4.
5. [ ] Serial Number	5.
6. [ ] Foreign/PCT Application Re:	6.
7. [ ] Other	7.

3. *(complete the following applicable item)*

The correction(s) is not due to any error by applicant and no fee is due.

OR

At least one of the above corrections is due to applicant's error and the fee therefore, under 37 C.F.R. Section 1.19(h), of \$25.00 is paid as follows:

Date: January 22, 2004

Respectfully submitted,



David S. Resnick (Reg. No. 34,235)  
Nicole L.M. Valtz (Reg. No. 47,150)  
NIXON PEABODY LLP  
101 Federal Street  
Boston, MA 02110  
(617) 345-6057/1270

BOS1342440.1

(Request for Corrected Filing Receipt - Page 2 of 2)




Q1PE  
UNITED STATES PATENT AND TRADEMARK OFFICE

JAN 26 2004

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (C) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/660,369	09/11/2003	1614	0.00	700953-54440	8	7	7

26248  
NIXON PEABODY LLP  
101 FEDERAL ST  
BOSTON, MA 02110



CONFIRMATION NO. 5464

FILING RECEIPT



\*OC000000011438546\*

Date Mailed: 12/09/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Ronald Levy, Stanford, CA;  
Dennis Panicali, Acton, MA;

**Assignment For Published Patent Application**

THERION BIOLOGICS CORPORATION, Cambridge, MA;  
The Board of Trustees of the Leland Stanford Junior University, Palo Alto, CA;

**Domestic Priority data as claimed by applicant**

This appln claims benefit of 60/410,161 09/12/2002

**Foreign Applications**

**If Required, Foreign Filing License Granted: 12/08/2003**

**Projected Publication Date: To Be Determined - pending completion of Missing Parts**

**Non-Publication Request: No**

**Early Publication Request: No**

**\*\* SMALL ENTITY \*\***

**Title**

*Costimulatory**B7.1**DELETE*

Transduced neoplastic cell preparations able to express T-cell preparations able to express T-cell  
costimulatory molecules B7-1, ICAM-1, and LFA-3 and induce immunostimulatory prophylactic  
and therapeutic anti-tumor effects in-vivo

**Preliminary Class**

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).